Literature DB >> 740047

Development of inactivated vaccine for Akabane disease.

H Kurogi, Y Inaba, E Takahashi, K Sato, Y Goto, K Satoda, T Omori, H Hatakeyama.   

Abstract

Virus inactivated by formalin or beta-propiolactone was superior to that inactivated by ether and heating in immunogenicity to mice. There were no significant differences in the antibody response of mice among such adjuvants as aluminum phosphate gel, aluminum hydroxide gel, and sodium arginate gel. When cattle were immunized with vaccine inactivated by formalin and adsorbed to aluminum phosphate gel, an excellent effect was obtained by injection with two doses of 3 ml each given at a 4-week interval. It was also suggested that mice and guinea pigs might be available for the potency test of vaccine. When calves and pregnant goats were injected with vaccine in the same manner as mentioned above, they were prevented from viremia and fetal infection caused by challenge virus. Even when stored at 4 degrees C for 12 months, vaccine was found to retain its stabilized immunogenicity. When pregnant cows were injected with vaccine in the field, the positive rate of neutralizing antibody was 88.5% in the 2 months after the first injection. When other pregnant cows were injected twice with vaccine, this rate was 34.6, 100, 65.4, and 45.8% in the 1, 2, 6, and 10 months, respectively, after the first injection. In another experiment, the antibody levels attained declined rather rapidly in several months. A single dose of vaccine given one year later provoked a rapid antibody response. The vaccination caused no clinical symptoms, abnormal birth, or decrease in milk yield in these cows.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 740047

Source DB:  PubMed          Journal:  Natl Inst Anim Health Q (Tokyo)        ISSN: 0027-951X


  8 in total

1.  Rapid detection of antigenic diversity of Akabane virus isolates by dot immunobinding assay using neutralizing monoclonal antibodies.

Authors:  K Yoshida; T Tsuda
Journal:  Clin Diagn Lab Immunol       Date:  1998-03

Review 2.  'Schmallenberg virus'--a novel orthobunyavirus emerging in Europe.

Authors:  M Beer; F J Conraths; W H M van der Poel
Journal:  Epidemiol Infect       Date:  2012-10-10       Impact factor: 4.434

3.  Evaluating the protective efficacy of a trivalent vaccine containing Akabane virus, Aino virus and Chuzan virus against Schmallenberg virus infection.

Authors:  Silke Hechinger; Kerstin Wernike; Martin Beer
Journal:  Vet Res       Date:  2013-12-05       Impact factor: 3.683

Review 4.  Bunyavirus-vector interactions.

Authors:  Kate McElroy Horne; Dana L Vanlandingham
Journal:  Viruses       Date:  2014-11-13       Impact factor: 5.048

5.  The N-terminal domain of Schmallenberg virus envelope protein Gc is highly immunogenic and can provide protection from infection.

Authors:  Kerstin Wernike; Andrea Aebischer; Gleyder Roman-Sosa; Martin Beer
Journal:  Sci Rep       Date:  2017-02-13       Impact factor: 4.379

Review 6.  Endemic and Emerging Arboviruses in Domestic Ruminants in East Asia.

Authors:  Tohru Yanase; Katsunori Murota; Yoko Hayama
Journal:  Front Vet Sci       Date:  2020-04-07

7.  Differentiation of Antibodies against Selected Simbu Serogroup Viruses by a Glycoprotein Gc-Based Triplex ELISA.

Authors:  Kerstin Wernike; Andrea Aebischer; Franziska Sick; Kevin P Szillat; Martin Beer
Journal:  Vet Sci       Date:  2021-01-18

8.  Bovine epizootic encephalomyelitis caused by Akabane virus in southern Japan.

Authors:  Ryota Kono; Miki Hirata; Masaya Kaji; Yukitoshi Goto; Shogo Ikeda; Tohru Yanase; Tomoko Kato; Shogo Tanaka; Toshiyuki Tsutsui; Tadao Imada; Makoto Yamakawa
Journal:  BMC Vet Res       Date:  2008-06-13       Impact factor: 2.741

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.